Stockscreener 앱 받기
7.68
1.92%
-0.15
시간 외 거래:
7.68
Zevra Therapeutics Inc 주식(ZVRA)의 최신 뉴스
Zevra therapeutics CFO sells shares for $86,471 - MSN
Zevra Therapeutics exec sells $23,587 in stock - MSN
Neil F. Mcfarlane Sells 61,273 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Stock - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) SVP Timothy J. Sangiovanni Sells 3,000 Shares - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) CFO Sells $86,460.00 in Stock - MarketBeat
Zevra Therapeutics exec sells $23,587 in stock By Investing.com - Investing.com Australia
Zevra therapeutics executive Joshua Schafer sells $82,526 in stock By Investing.com - Investing.com Australia
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of “Buy” by Analysts - Defense World
Brokers Issue Forecasts for ZVRA FY2029 Earnings - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Zevra Therapeutics CEO Neil McFarlane sells $727,389 in stock By Investing.com - Investing.com Canada
KemPharm Stock: Insider Sales Amid Strong Market Performance - sharewise
Zevra therapeutics CFO sells shares for $86,471 By Investing.com - Investing.com Nigeria
Zevra Therapeutics CEO Neil McFarlane sells $727,389 in stock - Investing.com India
Zevra therapeutics executive Joshua Schafer sells $82,526 in stock - Investing.com
Roth Capital Issues Optimistic Forecast for ZVRA Earnings - Defense World
Roth Capital Predicts Higher Earnings for Zevra Therapeutics - MarketBeat
(ZVRA) Investment Analysis - Stock Traders Daily
What is Roth Capital’s Forecast for ZVRA FY2029 Earnings? - Defense World
Stratos Wealth Partners LTD. Decreases Stock Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
2 ‘Strong Buy’ Growth Stocks Poised For 141% To 193% Gains, According To Wall Street - Barchart
2 ‘Strong Buy’ Growth Stocks Poised for 141% to 193% Gains, According to Wall Street - MSN
Hypersomnia Pipeline 2024: MOA, ROA, and Clinical Trial - openPR
BlackRock, Inc. Increases Stake in Zevra Therapeutics Inc. - GuruFocus.com
Zevra Therapeutics (NASDAQ:ZVRA) Upgraded by Cantor Fitzgerald to "Strong-Buy" Rating - MarketBeat
Janney Montgomery Scott LLC Has $2.48 Million Holdings in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Cantor Fitzgerald Upgrades Zevra Therapeutics (NASDAQ:ZVRA) to “Strong-Buy” - Defense World
Zevra Therapeutics to Present at the 21st Annual WORLDSymposium™ - GlobeNewswire
Breakthrough Treatment for Rare Brain Disease: Zevra's MIPLYFFA Earns Major Industry Recognition - StockTitan
Zevra Therapeutics to Participate at Upcoming Investor Conferences - The Manila Times
Rare Disease Leader Zevra Takes Center Stage at Major Healthcare Investment Events - StockTitan
Cantor Fitzgerald Predicts ZVRA FY2025 Earnings - Defense World
Cantor Fitzgerald Weighs in on ZVRA FY2025 Earnings - MarketBeat
Objective long/short (ZVRA) Report - Stock Traders Daily
Brokerages Set Zevra Therapeutics, Inc. (NASDAQ:ZVRA) PT at $21.57 - MarketBeat
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Rating of “Buy” by Analysts - Defense World
Barclays PLC Buys 42,926 Shares of Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - MarketBeat
Barclays PLC Has $399,000 Stake in Zevra Therapeutics, Inc. (NASDAQ:ZVRA) - Defense World
Positive Signs As Multiple Insiders Buy Zevra Therapeutics Stock - Yahoo Finance
Cantor Fitzgerald Weighs in on ZVRA FY2024 Earnings - Defense World
Learn to Evaluate (ZVRA) using the Charts - Stock Traders Daily
FY2024 EPS Forecast for Zevra Therapeutics Raised by Analyst - MarketBeat
Zevra Therapeutics (NASDAQ:ZVRA) Coverage Initiated at Cantor Fitzgerald - Defense World
0.27%
3.05%
자본화:
|
볼륨(24시간):